Gene Therapy for Huntington's Disease Seeks US Approval

For families watching loved ones lose control of their movements, memories, and minds to Huntington's disease, a game-changing treatment just moved one giant step closer to reality.

Dutch biotech company uniQure has submitted applications to the FDA and UK health authorities seeking approval for AMT-130, a one-time gene therapy administered directly into the brain. The treatment aims to silence the faulty gene that causes Huntington's, a genetic disorder with no cure and limited treatment options.

The therapy isn't a cure, but clinical trial results offer real hope. Over three years, patients who received a high dose of AMT-130 showed 75% slower disease progression compared to untreated patients tracked in natural history studies.

AMT-130 works by targeting the root cause of Huntington's: mutations that produce toxic versions of the huntingtin protein. Once delivered through brain surgery, the gene therapy instructs cells to stop making this harmful protein.

The FDA initially wanted uniQure to conduct an additional trial before applying for approval. But this summer, the agency reversed course and agreed that existing data from trials in the US and Europe were strong enough to move forward under the accelerated approval pathway.

This pathway allows promising treatments for serious conditions to reach patients faster based on early evidence. If approved, uniQure will need to conduct additional studies to confirm the therapy's long-term benefits.

"The submission of licensing applications represents an important milestone for the Huntington's disease community," said Matt Kapusta, uniQure's CEO. The company plans to present four-year trial data in the coming months.

The FDA typically takes 10 months to review applications, though uniQure has requested priority review, which would cut that time to six months. The therapy has already received several special designations meant to speed development of treatments that fill urgent medical needs.

Why This Inspires

Huntington's disease affects about 30,000 Americans, with another 200,000 at risk of inheriting the fatal genetic mutation. Families often watch multiple generations suffer through the same devastating decline, knowing each child of an affected parent has a 50% chance of inheriting the disease.

This therapy represents the first real shot at changing that trajectory. While not a cure, slowing progression by three-quarters could mean years more of independence, clear thinking, and quality time with loved ones.

The story also shows how regulatory agencies can adapt when patients need them most. The FDA's willingness to work with uniQure on a faster pathway demonstrates that scientific rigor and compassionate urgency can work together.

For thousands of families living in the shadow of Huntington's, this regulatory milestone transforms "someday" into "maybe soon."